Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure.
about
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney diseaseSympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney diseaseAutonomic and inflammatory consequences of posttraumatic stress disorder and the link to cardiovascular diseaseDifferential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease.The cardiorenal syndrome: making the connection.Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis.The severe cardiorenal syndrome: 'Guyton revisited'.Heart rate response to blood pressure variations: sympathetic activation versus baroreflex response in patients with end-stage renal diseaseTetrahydrobiopterin lowers muscle sympathetic nerve activity and improves augmentation index in patients with chronic kidney disease.A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fractionAbnormal neurocirculatory control during exercise in humans with chronic renal failure.Effects of eprosartan on target organ protection.Pathogenesis of hypertension in renal failure: role of the sympathetic nervous system and renal afferents.Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients.Exercise pressor response and arterial baroreflex unloading during exercise in chronic kidney disease.Exercise training improves cardiovascular autonomic activity and attenuates renal damage in spontaneously hypertensive rats.Central sympathetic overactivity: maladies and mechanisms.Essential hypertension: an approach to its etiology and neurogenic pathophysiology.Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST study.Enalapril attenuates the exaggerated sympathetic response to physical stress in prenatally programmed hypertensive rats.The role of sympathetic nervous activity in renal injury and end-stage renal disease.Sympathetic mechanisms, organ damage, and antihypertensive treatment.Animal models of cardiorenal syndrome: a review.Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity.Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options.Pharmacologic treatment of hypertension in patients with chronic kidney disease.The sympathetic nervous system in chronic kidney disease.Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress?The role of the kidney and the sympathetic nervous system in hypertension.Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients.Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review.Uraemia: an unrecognized driver of central neurohumoral dysfunction in chronic kidney disease?Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms.Cardiovascular risk in chronic kidney disease: role of the sympathetic nervous system.L/T-type calcium channel blocker reduces non-Gaussianity of heart rate variability in chronic kidney disease patients under preceding treatment with ARB.Major pathways of the reno-cardiovascular link: the sympathetic and renin-angiotensin systems.Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life.Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial.Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.Sympathetic function during whole body cooling is altered in hypertensive adults.
P2860
Q24235834-92185AC4-7AA6-48DB-80CA-54D5A32E19F9Q24617193-689702DB-6E22-4C60-AC1F-688FDB3B5B88Q28081985-38D7AAFE-6D79-468C-A74E-366A485CE6B6Q30484944-4F9DE934-4044-4905-8383-A7295475D82AQ34340391-60C06D9A-78A6-489E-A8E5-DF4F8C2F3BE6Q34358545-75CE7C1C-70F3-4A66-9D0F-01E420CF0982Q34379161-FCA4D85A-CC79-44EF-AF57-681A04E6D27DQ35017162-B8810038-9114-4C7B-9D4E-A3E70B7D788AQ35035498-0D9E5179-FF68-4144-AD6C-58B6DB2F627FQ35057999-2C3EF5A3-3767-4565-B31B-1DE1F3AFABD6Q35107987-2E9BA85F-0E24-451C-BF47-7C48852C1510Q36012913-EA2ABAED-AD18-4B6F-893F-2AFCBF06B3B7Q36107868-97F837DD-E5AE-4A64-A48A-48E8D9C74CE0Q36701855-D183D590-D409-41A9-95CA-6541417699E9Q36737696-2872C178-5505-420F-A1BD-41028B1181F0Q37143954-EFB2233A-A96E-4A1E-A08A-12B2E5F0E9E6Q37186153-99B3B8A9-8416-454D-A2F1-C731562859BEQ37412877-ABB4CCDB-907D-436C-9722-EE3A4AC22F97Q37449319-0904B731-DA72-4DBA-B395-DB9AB39E9F40Q37477116-EB6D7759-F070-4F2B-B828-A95446591371Q37719241-B14D6AE0-9F01-45F8-B503-1E4848B8B610Q37859637-8CAE91DC-32D6-41AB-8A12-5D78FCE8F5C7Q37930478-991E5D70-87E6-416A-B584-C4DE3894B6FFQ37987922-97EF0BA8-24C2-42C8-A196-FCE12D009047Q38077127-4ABF8E98-2A36-474F-99EF-827C9F7CB3C5Q38095805-5A81FE0F-16AB-4337-960D-11B3E1B6A73AQ38112066-94A0A527-80FF-48FE-B4DB-B7F1E2D819A1Q38165049-7FE92C1E-7EA4-4412-A60D-AD5474F38C93Q38194474-A9C28C02-BF4A-4EA4-923D-99688B28E9F3Q38492588-A2483F57-39FD-469E-8081-3B7036BD9842Q38527010-5E5CC0C0-5B7D-48DE-80E9-88192A631F86Q38849711-86732725-67E0-487F-BDFB-43E0F09DB30DQ41573480-E748B167-95F2-470E-8709-FDC04742D2C9Q41838379-0ED68665-9D13-4EEB-B11D-5446E4203CC6Q41946779-AEB36E12-2183-41EA-887F-C74AD591CA25Q42727670-CD11ACDA-BA8C-45C5-B41A-179AC0DA452FQ43225774-4093A2F7-97B2-4C19-8944-B6C7880316F0Q45240573-93A7FC12-43FB-4E00-AE8E-AA8A691F88EEQ46039857-594A8294-BAD6-448B-BFD6-1B83C4A60568Q47885896-FA6CF476-776D-4E2C-84E6-D8D5A6E59E20
P2860
Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Enalapril and losartan reduce ...... ts with chronic renal failure.
@en
Enalapril and losartan reduce ...... ts with chronic renal failure.
@nl
type
label
Enalapril and losartan reduce ...... ts with chronic renal failure.
@en
Enalapril and losartan reduce ...... ts with chronic renal failure.
@nl
prefLabel
Enalapril and losartan reduce ...... ts with chronic renal failure.
@en
Enalapril and losartan reduce ...... ts with chronic renal failure.
@nl
P2093
P1476
Enalapril and losartan reduce ...... ts with chronic renal failure.
@en
P2093
Gerry Ligtenberg
Hein A Koomans
Inge H H T Klein
P Liam Oey
Peter J Blankestijn
P304
P356
10.1097/01.ASN.0000045049.72965.B7
P577
2003-02-01T00:00:00Z